Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 0.74 |
| ▸ | LCK | P06239 | 4/20 | 0.74 |
| ▸ | LYN | P07948 | 3/20 | 0.74 |
| ▸ | NUDT14 | O95848 | 2/20 | 0.67 |
| ▸ | NUDT5 | Q9UKK9 | 2/20 | 0.67 |
| ▸ | SRC | P12931 | 2/20 | 0.65 |
| ▸ | KDR | P35968 | 2/20 | 0.65 |
| ▸ | TEK | Q02763 | 1/20 | 0.65 |
| ▸ | EGFR | P00533 | 4/20 | 0.61 |
| ▸ | ITK | Q08881 | 3/20 | 0.61 |
| ▸ | TEC | P42680 | 3/20 | 0.60 |
| ▸ | BMX | P51813 | 3/20 | 0.60 |
| ▸ | TXK | P42681 | 2/20 | 0.60 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.60 |
| ▸ | FLT3 | P36888 | 2/20 | 0.60 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.60 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.60 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.60 |
| ▸ | LATS1 | O95835 | 1/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22243309 | 1.00 | BTK (0.74) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL29441901 | 1.00 | BTK (0.74) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL22243327 | 1.00 | BTK (0.74) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL22243326 | 0.95 | BTK (0.71) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL24041260 | 0.89 | BTK (0.76) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL22243246 | 0.89 | BTK (0.76) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL22243245 | 0.89 | BTK (0.76) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL29441895 | 0.89 | BTK (0.76) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL22243253 | 0.88 | BTK (0.72) | BTKLCKLYNNUDT14NUDT5 | |
| SCHEMBL22230750 | 0.88 | BTK (0.72) | BTKLCKLYNNUDT14NUDT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220081445-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | MINGHUI PHARMACEUTICAL SHANGHAI LTD (CN) | 2022-03-17 | — | — | US | claimed |
| US-12384786-B2 | Cyclic molecules as Bruton's tyrosine kinase inhibitor | MINGHUI PHARMACEUTICAL SHANGHAI LTD (CN) | 2025-08-12 | — | — | US | disclosed |
| CN-111454268-B | Cyclic molecules as inhibitors of bruton's tyrosine kinase | 明慧医药（上海）有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-116589465-A | Cyclic molecules as inhibitors of bruton's tyrosine kinase | 明慧医药（上海）有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-113710671-B | Cyclic molecules as inhibitors of bruton's tyrosine kinase | 明慧医药（上海）有限公司 | 2023-04-28 | — | — | CN | disclosed |
| US-20220081445-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | MINGHUI PHARMACEUTICAL SHANGHAI LTD (CN) | 2022-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384786-B2 | Cyclic molecules as Bruton's tyrosine kinase inhibitor | ABL1, BTK, LYN | BTK 2/4885LCK 7/4885LYN 3/4885 |
| US-20220081445-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | ABL1, BTK, LYN | BTK 2/4885LCK 7/4885LYN 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.